As India and the United States begin a fresh round of trade negotiations in New Delhi from June 1 to June 4, the pharmaceutical sector has emerged as one of the most closely watched areas of discussion. The talks are expected to focus on tarif...
Zydus Lifesciences gains US FDA priority review for saroglitazar in PBC, strengthening its specialty pipeline amid rising global demand for liver disease therapies.
Cipla targets 50 global filings, focusing on innovation, biosimilars, and complex generics to expand US and Europe presence and strengthen chronic therapy leadership.
India clears Wockhardt’s Zaynich, a novel antibiotic for drug-resistant infections, backed by strong Phase 3 data, offering an effective treatment option for complicated UTIs and severe Gram-negative cases.
P&G Health stock surges 18% after strong Q4 results with 56% profit growth and margin expansion, driven by brand strength, supply chain efficiency, and steady demand outlook.
Tieten Medicity Hospital has successfully performed one of Thane’s first robotic telesurgeries for gall bladder removal (robotic cholecystectomy) using the indigenously developed Mizzo Endo 4000 robotic surgical system.
Sun Pharma reported a strong financial performance for the fourth quarter of FY26, with Sun Pharma Q4 revenue rising 13.6 per cent to Rs. 14,560 crore and Sun Pharma net profit jumping 26.2 per cent to Rs. 2,714 crore, reflecting healthy growt...
.jpeg)
Indian drugmakers deepen US market focus despite export decline in FY26, driven by pricing pressure, generics slowdown, and shift toward specialty drugs and local manufacturing.
Venus Remedies has strengthened its footprint in the Gulf region after receiving Marketing Authorization from the Saudi Food and Drug Authority for Plerixafor, a specialty injectable used in stem cell transplantation procedures.
The pharmaceutical outsourcing landscape is undergoing its most consequential structural transformation in decades—and Indian CDMO players are leading the charge. As global drug innovators race to compress timelines and de-risk capital-intensive...
.jpg)
, CDSCO.jpg)